Common Contracts
3 similar Underwriting Agreement contracts by Nlight, Inc., Proteon Therapeutics Inc
EX-1.1 2 a2235251zex-1_1.htm EX-1.1 [Number of Firm Shares] Shares NLIGHT, INC. Common Stock UNDERWRITING AGREEMENT STIFEL, NICOLAUS & COMPANY, INCORPORATED RAYMOND JAMES & ASSOCIATES As representatives of the several Underwriters named in Schedule I...Underwriting Agreement • May 5th, 2020 • New York
nLIGHT, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”), an aggregate of [·] shares (the “Firm Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional [·] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
Number of Firm Shares] Shares NLIGHT, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 16th, 2018 • Nlight, Inc. • Semiconductors & related devices • New York
nLIGHT, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”), an aggregate of [·] shares (the “Firm Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional [·] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
UNDERWRITING AGREEMENT [Number of Firm Shares] Shares Proteon Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 7th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”), an aggregate of [·] shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional [·] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
